---
schema_version: "secwatch.filing_event.v1"
accession: "0000950103-26-011979"
form_type: "8-K"
ticker: "BLCO"
cik: "0001860742"
company_name: "Bausch & Lomb Corp"
filed_at: "2026-08-06T11:10:22+00:00"
generated_at: "2026-08-06T11:15:29.240184+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bausch + Lomb appoints four new directors, reaffirms 2026 guidance after Q2 revenue of $1.394B

## Summary
- Q2 revenue $1.394B, up 9% reported and 8% constant currency vs Q2 2025; broad-based double-digit growth in Surgical and Pharma.
- Cash flow from operations rose to $153M in Q2 from $32M in Q1; adjusted cash flow from operations $161M.
- Full-year 2026 guidance reaffirmed: revenue $5.44B–$5.54B, Adj EBITDA (ex-IPR&D) $1.025B–$1.075B.
- Board adds Thomas Appio (CEO of Bausch Health), Robert Chersi, Laurence Paul, and Barbara Trebbi; four prior directors resigned.
- Resignations not due to disagreement; departing directors receive prorated cash and full RSU vesting; Thomas Ross gets $400K consulting fee.

## SEC filing metadata
- accession: 0000950103-26-011979
- form_type: 8-K
- ticker: BLCO
- cik: 0001860742
- company_name: Bausch & Lomb Corp
- filed_at: 2026-08-06T11:10:22+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860742/000095010326011979/0000950103-26-011979-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860742/000095010326011979/dp251415_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950103-26-011979
- JSON: https://secwatch.observer/filing/0000950103-26-011979.json
- Plain text: https://secwatch.observer/filing/0000950103-26-011979.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.